∙ A subject will be eligible for study participation if he/she meets the following criteria:

• Subjects are eligible with B-cell malignancies, WM, FL, MCL, MZL, DLBCL, HCL, CLL, SLL, based upon 2016 updated WHO classification. Those subjects with WM, FL, MCL, DLBCL, or HCL must have received at least 2 prior systemic therapies.

• Low-grade B-cell lymphomas as follicular Grade 1, 2, or 3A, marginal zone or small lymphocytic lymphoma.

• Subject must have adequate coagulation, renal, and hepatic function, per local laboratory reference ranges at Screening as follows:

‣ Activated partial thromboplastin time (APTT) and prothrombin time (PT) not to exceed 1.5 × ULN

⁃ Calculated creatinine clearance (CrCl) ≥ 60 mL/min using 24-hour CrCl OR Cockcroft-Gault formula.

⁃ Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 1.5 ×ULN; Bilirubin ≤ 1.5 × ULN (except subjects with Gilbert's Syndrome, who may have a bilirubin \> 1.5 × ULN, per discussion between the Investigator and the Medical Monitor).

• Subjects must have adequate bone marrow independent of growth factor support per local laboratory reference range at screening as follows:

‣ Absolute Neutrophil Count (ANC) ≥1000/uL;

⁃ An exception is for subjects with an ANC\<1000/uL and bone marrow heavily infiltrated with underlying disease (approximately 60% or more) may use growth factor to achieve the ANC eligibility criteria per discussion between the Investigator and the Medical Monitor.

⁃ Platelet count ≥ 50,000/µL - OR - Platelet count ≥ 20,000/ µL if thrombocytopenia is clearly due to CLL disease under study (per Investigator discretion)

⁃ Hemoglobin ≥8.0g/dL, and can be achieved by transfusion